natural surfactants consist unique proteins lipids effectiveness improving subnormal lung function surfactant deficiency established prior clinical trials rigorous tests required document batch batch variability surface activity exclude toxic contaminants date randomized clinical trials small preterm infants demonstrated striking improvement lung function decrease incidence acute complications pneumothorax interstitial emphysema administration human surfactant birth severe rds decreased deaths incidence bronchopulmonary dysplasia homologous surfactant advantageous heterologous terms acute beneficial effects lung function safety efficacy animal surfactant improving outcome remains established human surfactant serve model unlimited natural surfactant produced gene technology pharmacodynamics aspects surfactant substitution indications exogenous surfactant management patients undergoing surfactant substitution remain studied exogenous surfactant offers potential treat prevent severe respiratory failure infants children adults